FENNEC PHARMACEUTICALS INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 09/30/23 | FY 12/31/22 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $44.6M | $47.5M | $23.8M | — | $1.8M |
| Cost of revenue | — | — | $1.3M | — | $86,000 |
| Gross profit | — | — | $20.0M | — | $1.4M |
| Research and development | $250,000 | $307,000 | $56,000 | — | $3.5M |
| Operating expenses | $50.9M | $45.0M | $34.0M | — | $24.0M |
| Operating income | -$6.3M | $2.6M | -$12.8M | — | -$22.6M |
| Pretax income | -$9.6M | -$71,000 | -$16.0M | — | — |
| Income tax expense | $106,000 | $365,000 | — | — | $0 |
| Net income | -$9.7M | -$436,000 | -$16.0M | — | -$23.7M |
| Balance Sheet | |||||
| Cash and equivalents | $36.8M | $26.6M | $13.3M | — | $23.8M |
| Current assets | $67.0M | $44.1M | $26.9M | $19.9M | $26.7M |
| Total assets | $70.6M | $44.9M | $26.9M | $20.0M | $26.9M |
| Current liabilities | $10.5M | $6.9M | $7.6M | — | $4.6M |
| Total liabilities | $35.1M | $50.8M | $38.5M | — | $29.5M |
| Total debt | — | $18.2M | $30.0M | — | $25.0M |
| Stockholders' equity | $35.5M | -$5.9M | -$11.6M | $9.6M | -$2.6M |
| Cash Flow Statement | |||||
| Cash from operations | -$12.5M | $27.0M | -$17.1M | — | -$18.1M |
| Stock-based compensation | $7.0M | $5.1M | $5.4M | — | $4.1M |
| Capital expenditure | — | — | — | — | $175,000 |
| Free cash flow | — | — | — | — | -$18.2M |
Shares outstanding 34.7M · Free float 79.9%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.